Incidence, Risk Factors, and Mortality Associated With Second Malignant Neoplasms Among Survivors of Adolescent and Young Adult Cancer | Zendy

Chun Chao | Zendy; Smita Bhatia | Zendy; Lanfang Xu | Zendy; Kimberly L. Cannavale | Zendy; F. Lennie Wong | Zendy; Poyin Huang | Zendy; Robert Cooper | Zendy; Saro H. Armenian | Zendy

Open Access

Incidence, Risk Factors, and Mortality Associated With Second Malignant Neoplasms Among Survivors of Adolescent and Young Adult Cancer

Author(s) -

Chun Chao,

Smita Bhatia,

Lanfang Xu,

Kimberly L. Cannavale,

F. Lennie Wong,

Poyin Huang,

Robert Cooper,

Saro H. Armenian

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2019.5536

Subject(s) - medicine , poisson regression , cancer , epidemiology , incidence (geometry) , cohort , retrospective cohort study , young adult , survivorship curve , epidemiology of cancer , pediatrics , oncology , population , breast cancer , environmental health , physics , optics

Key Points Question What are the incidence patterns and risk factors for second malignant neoplasms (SMN) among survivors of adolescent and young adult cancer? Findings This cohort study of 10 574 survivors of adolescent and young adult cancer found that these individuals had a 2.6-fold greater risk of developing SMN compared with individuals with no history of cancer. Risk factors for SMN included demographic factors, stage at diagnosis, and radiation therapy and varied by first cancer type, with survivors of breast cancer, melanoma, and testicular cancer having substantially elevated risk for SMN of the same type. Meaning This study suggests that SMN risk is elevated in survivors of adolescent and young adult cancer and provides data that may be used to identify individuals at high risk and inform screening for SMN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research